Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026)
Maze Therapeutics recorded quarterly Depreciation & Amortization (CF) of $444000.0 in Q1 2026, down 11.02% quarter-over-quarter from $499000.0 in Q4 2025, and down 35.09% year-over-year from $684000.0 in Q1 2025.
Maze Therapeutics' Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $444000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 35.09% year-over-year to $444000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 28.71% YoY), while the FY2025 annual figure was $2.4 million, down 27.18% from the prior year.
- Depreciation & Amortization (CF) came in at $444000.0 for Q1 2026 at Maze Therapeutics, down from $499000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $950000.0 in Q1 2024 to a low of $444000.0 in Q1 2026.
- A 3-year average of $683000.0 and a median of $684000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) decreased 24.0% in 2025 and tumbled 35.09% in 2026, its largest moves.
- Maze Therapeutics' Depreciation & Amortization (CF) stood at $708000.0 in 2024, then retreated by 29.52% to $499000.0 in 2025, then declined by 11.02% to $444000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $444000.0, $499000.0, and $571000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | 444,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 444,000.00 |
| Mar 31, 2026 | 444,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Dec 31, 2025 | 499,000.00 |
| Sep 30, 2025 | 571,000.00 |
| Sep 30, 2025 | 571,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Jun 30, 2025 | 649,000.00 |
| Mar 31, 2025 | 684,000.00 |
| Mar 31, 2025 | 684,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Dec 31, 2024 | 708,000.00 |
| Sep 30, 2024 | 788,000.00 |
| Sep 30, 2024 | 788,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Jun 30, 2024 | 854,000.00 |
| Mar 31, 2024 | 950,000.00 |
| Mar 31, 2024 | 950,000.00 |